Abstract Dynamic interactions between tumorigenic cells and surrounding cells, including immunomodulatory hematopoietic cells, can dictate tumor initiation, progression, and transformation. Hematopoietic-stromal interactions underpin the plexiform neurofibroma, a debilitating tumor arising in individuals afflicted with Neurofibromatosis type 1 (NF1), a common genetic disorder resulting from mutations in the NF1 tumor suppressor gene. At the tissue level, plexiform neurofibromas demonstrate a complex microenvironment composed of Schwann cells, fibroblasts, perineural cells, mast cells, secreted collagen, and blood vessels. At the cellular level, specific interactions between these cells engender tumor initiation and progression. In this microenvironment hypothesis, tumorigenic Schwann cells secrete pathological concentrations of stem cell factor, which recruit c-kit expressing mast cells. In turn, activated mast cells release inflammatory effectors stimulating the tumorigenic Schwann cells and their supporting fibroblasts and blood vessels, thus promoting tumor expansion in a feed-forward loop. Bone marrow transplantation experiments in plexiform neurofibroma mouse models have shown that tumorigenesis requires Nf1 haploinsufficiency in the hematopoietic compartment, suggesting that tumor microenvironments can depend on intricate interactions at both cellular and genetic levels. Overall, our continued understanding of critical tumor-stromal interactions will illuminate novel therapeutic targets, as shown by the first-ever successful medical treatment of a plexiform neurofibroma by targeted inhibition of the stem cell factor/c-kit axis.
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Keywords NF1 . Tumor microenvironment . Mast cells . Neurofibromas Also known as von Recklinghausen's disease, Neurofibromatosis type 1 (NF1) is a pandemic genetic disorder afflicting about 1 in 3,000 persons worldwide [1] . NF1 occurs as consequences of mutations of NF1 tumor suppressor gene on the long arm of chromosome 17, a gene encoding neurofibromin [2] . Neurofibromin functions as a Ras GTPase activating protein (Ras-GAP), which accelerate the hydrolysis of active GTP-bound Ras to inactive GDP-bound Ras [3, 4] . NF1 is highly conserved across species, especially in the functionally critical GAP-related domain [4, 5] .
Although disease penetrance is complete, specific manifestations can vary widely from patient to patient. Patients are predisposed to both malignant and non-malignant conditions, such as cutaneous neurofibromas, plexiform neurofibromas, malignant peripheral nerve sheath tumors (MPNSTs), myeloid leukemia, vascular pathologies, and soft tissue malformation [6, 7] . Approximately 30 % of individuals with NF1 suffer from plexiform neurofibromas, a tumor suspected to arise during gestation which can be an early source of disfigurement, disability, and lethality [8] . Intriguingly, plexiform neurofibromas demonstrate an intricate microenvironment composed of irregularly growing Schwann cells, large numbers of degranulating mast cells, perineural cells, collagen-secreting fibroblasts, and blood vessels.
Studies in other cancer models have demonstrated that tumorigenic cells and their inflammatory microenvironment affect tumor cell growth, transformation, and metastasis [9] . Although cancers frequently originate secondary to activation of oncogenes or alternatively as a loss of tumor suppressor genes in proliferating cells, it has become increasingly evident that a single mutagenic event is rarely sufficient for oncogenesis [10] . In a range of murine tumor models including breast, ovarian [11] , pancreatic [12] , and skin models [13] , inflammatory cells play critical roles in maintaining the microenvironment that supports tumor genesis, progression, and transformation.
Microenvironments consist of various cell types, cytokines, growth factors, and components of the extracellular matrix. Importantly, the microenvironment, as a dynamic entity, differs in cellular and molecular specificity according to both tumor type and disease stage. For example, early cues from nascent tumor cells can recruit hematopoietic cells which secrete factors to promote local mitogenesis as well as the recruitment of additional immunomodulators. Further secretion of secreted cytokines and growth factors not only remodels the extracellular matrix and the vasculature, but also may provide the specific signals permitting cellular transformation and metastasis.
Mast cells are granular, tissue-resident immune effector cells derived from early myeloid progenitor cells in hematopoietic tissue [14] . Upon activation of the high-afinity IgE receptor (Fc RI) and/or the c-kit receptor tyrosine kinase, mast cells release inflammatory mediators including histamine, serotonin, proteoglycans, and leukotrienes [15] . In various disease models, mast cells can both positively and negatively regulate inflammation [16, 17] . In NF1-associated plexiform neurofibromas, inflammatory mast cells not only pervade tumor tissue and promote cellular growth [18] [19] [20] [21] [22] [23] [24] [25] , but they appear to be required for tumorigenesis. As support, hematopoietic ablation of the gene encoding the receptor tyrosine kinase c-kit (a key regulator of mast cell generation and bioactivity) prevents tumorigenesis in a plexiform neurofibroma murine model [25] . Furthermore, imatinib mesylate (Gleevec©), an inhibitor of ckit and other receptor tyrosine kinases, successfully reduced a highly morbid plexiform neurofibroma in a pediatric patient with NF1 [25] .
The presence of mast cells in tumor tissue of neurofibromas was initially reported by Greggio in 1911 [26] .
Independent groups later reported the existence of mast cells within peripheral nerve sheaths, nerve sheath tumors, and NF1-associated neurofibromas [27] [28] [29] [30] [31] . Further histological analyses have shown significant increases of mast cell number in only the neurofibroma tissue, as compared to surrounding tissue [32] . Based on these observations and his own clinical observations, Vincent Riccardi hypothesized that mast cells might directly modulate neurofibroma tissue [33] , although histamine-release inhibitors, while effective at symptom control, ultimately did not affect neurofibroma progression [34, 35] .
Mouse models of plexiform neurofibroma formation have illuminated cellular and molecular interactions underpinning the tumor microenvironment while providing new insight into targeted therapeutic strategies. Zhu et al. created the first successful mouse model mimicking human neurofibroma genesis [18] . This mouse carries Cre recombinase placed under control of the Krox20 promoter (Krox20cre), a promoter element preferentially expressed in a subset of Schwann cells. Surprisingly, Krox20cre mice crossed into mice with mice carrying two distinct W mutations, a mutation which compromises c-kit receptor tyrosine kinase activity and inhibits mast cell production and bioactivity [36] . [20, [38] [39] [40] . Moreover, SCF-stimulated Nf1 +/− mast cells, as compared to WT mast cells, proliferate more quickly, demonstrate enhanced survival, and secrete greater concentrations of inflammatory cytokines [38, [41] [42] [43] . In a subsequent study, SCF-stimulated Nf1 +/− mast cells promoted fibroblast growth and collagen deposition [38] , key cellular components of human neurofibromas [44] .
These mechanistic insights propelled investigation into pharmacological inhibition of c-kit as a method to reduce and/or inhibit plexiform neurofibromas. Imatinib mesylate binds and inhibits the c-kit receptor tyrosine kinase, as well as c-abl, PDGF-β, TGF-β, and perhaps other RTKs [45] . Indeed, imatinib treatment of adult Krox20creNf1 flox/− mice reduced neurofibroma volume and metabolism approximately 50 % as compared to placebo-treated controls. Nerve sheath samples from these mice showed restoration of morphology to Schwann cells and the absence of mast cells. Furthermore, imatinib treatment of a pediatric index patient with a debilitating neurofibroma reduced tumor volume 70 % while mitigating symptoms of airway and nerve compression [25] .
Collectively, these genetic and pharmacological data argue that Nf1-deficient Schwann cells recruit and activate marrow-derived mast cells, which critically modulate tumor genesis and growth. While data from certain mouse models suggest that tumor formation requires Nf1 +/− mast cells, other models using developmentally earlier and more widespread glial cell deletions have not shown this requirement for Nf1 +/− mast cells [46] . Regardless, all mouse models to date have shown the pervasive presence of degranulating mast cells within the tumor tissue.
The tumor microenvironment is complex and dynamic, and varies depending on the type of tumor or cancer. Here, we have summarized historical and current evidence regarding the inflammatory microenvironment of the plexiform neurofibroma. SCF-recruited mast cells secrete multiple key growth factors that modulate the behavior of the neurofibroma stroma, and these mechanistic insights have led to a promising therapeutic strategy. Further studies of the cellular/molecular interactions between tumor, hematopoietic, and stromal cells in the neurofibroma microenvironment will undoubtedly unravel more clues in the search for targeted therapeutic interventions.
